Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose safety, tolerability, and pharmacokinetics of FE 999301 in healthy Japanese men
jRCT2071240029Phase 1Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals Co., Ltd.
- Start
- Jul 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing FE 999301 single IV dose with Placebo single IV dose (2 arms). Primary endpoints: Treatment-emergent adverse events and Change from baseline in safety parameters. Started Jul 2024; status: active, not recruiting.
02
Drugs
olamkicept
Beyond the preview
Go deeper on jRCT2071240029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240029.